Wright JD et al. - Bevacizumab demonstrates promising activity in recurrent ovarian cancer. The addition of a cytotoxic agent to bevacizumab improved response rates, however at the cost of increased toxicity. The perforations occurred in heavily pretreated patients (7%) who were responding to therapy. Methods
A retrospective review of pts with recurrent ovarian cancer treated with bevacizumab
Response was determined radiographically and through CA125 measurements
Statistical analysis to determine factors associated with toxicity and response was performed
62 eligible pts were identified
The cohort had received a median of 5 prior chemotherapy regimens
Single-agent bevacizumab was administered to 19%, while 81% received the drug in combination with a cytotoxic agent
Results
Grade 3-5 toxicities occurred in 24% pts, including grade 3-4 hypertension in 7%, gastrointestinal perforations in 7%, and chylous ascites in 5%
Development of chylous ascites and gastrointestinal perforations appeared to correlate with tumor response
The ORR was 36% (4 CR, 17 PR), with SD in 40%
A higher ORR was seen in the bevacizumab combination group vs single-agent treatment
However, 29 grade 3-5 toxic episodes were seen in the combination group vs only 1 in the single-agent bevacizumab cohort
See all
